Ophthalmic Clinical Trial FAQs

Unlike fixed-location sites that require participants to travel, 20/20 Onsite brings calibrated equipment and trained ophthalmic clinicians to participants, which improves access, retention, and data consistency. Here’s how 20/20 Onsite is different from legacy sites:

1. Point-of-Need Accessibility: Unlike legacy sites, which require participants to travel, 20/20 Onsite brings state-of-the-art, point-of-need ophthalmic assessments directly to trial participants wherever they are: home, work, or even school.
2. Patient-Centric Model: By minimizing patient travel and scheduling inconvenience, 20/20 Onsite increases engagement and retention. 20/20 Onsite's point-of-need clinics help ensure trials stay on track with high participant satisfaction and a 95+ Net Promoter Score.
3. Enhanced Enrollment and Diversity: Fixed-location sites often limit access to patients within a specific geography, resulting in the underrepresentation of diverse populations. 20/20 Onsite’s point-of-need clinics enable recruitment from a broader and more diverse demographic, addressing a crucial need in clinical trials to meet enrollment goals effectively. 
4. Cost Control and Efficiency: Trial delays can cost sponsors millions daily. 20/20 Onsite's point-of-need service model is designed to meet strict timelines, reduce logistical delays, and enable sponsors to manage budgets better. 

Overall, 20/20 Onsite offers a streamlined, patient-centered alternative that overcomes the traditional limitations of fixed-location clinical trial sites.

20/20 Onsite’s point-of-need service model eliminates the significant barriers that traditional fixed-location sites face, offering pinpoint accessibility and predictable timing by reaching trial participants exactly where they live or work. Reaching participants is especially critical when, per a 2020 JMIR review, 80% of clinical trials fail to meet enrollment timelines, delays that can cost sponsors up to $8 million per day, alongside an industry dropout rate near 30%. By delivering assessments directly to participants, 20/20 Onsite reduces selection bias, expands trial reach, accelerates enrollment, and minimizes dropout rates, ensuring trials are completed on time and on budget.

On the other hand, legacy sites rely solely on motivated patients who can travel, a necessity that limits diversity and increases recruitment challenges. 20/20 Onsite’s Net Promoter Score of 95+ reflects high participant satisfaction, boosting retention and engagement throughout the study.

Additionally, legacy sites often struggle to reach underserved or remote populations. However, 20/20 Onsite eliminates this issue by providing point-of-need clinics, delivering high-quality, patient-centric care anywhere needed. This flexibility improves patient satisfaction and enhances trial integrity and data quality, making 20/20 Onsite a cost-effective and superior solution for clinical trials.

20/20 Onsite performs baseline and follow-up ocular safety assessments, including BCVA, intraocular pressure, slit lamp biomicroscopy, dilated fundus exams, OCT, fundus photography, and visual field testing. It also supports post-market safety surveillance eye exams, so participants avoid an extra trip to another provider.

Patient details, including contact and location information, are shared with 20/20 Onsite only after appropriate consent has been obtained. 20/20 Onsite recommends including its name in the Informed Consent Form (ICF) language, explicitly authorizing 20/20 Onsite to directly contact participants for scheduling and logistical coordination of study visits. If direct outreach consent is not included in the ICF, 20/20 Onsite can instead coordinate through the research site, which would act as the intermediary in facilitating scheduling and communications with participants. All data collection is done over the phone and stored in our secure and compliant platform, consistent with HIPAA and GDPR requirements, as applicable.